Somatostatin analogs in rheumatoid arthritis and other inflammatory and immune-mediated conditions

Current Opinion in Investigational Drugs

Volumn 4, Issue 5, 2003, Pages 578-582

  Paran, Daphna ^a   Paran, Haim ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

Neuropeptide; Rheumatoid arthritis; Somatostatin

Indexed keywords

ANGIOPEPTIN; ANTIRHEUMATIC AGENT; BROMOCRIPTINE; OCTREOTIDE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; VAPREOTIDE;

ABDOMINAL CRAMP; ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; BLOATEDNESS; CELL FUNCTION; CHOLESTEROL STONE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOXICITY; ERYTHEMA; ERYTHRODERMA; GASTROINTESTINAL SYMPTOM; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATION; INJECTION PAIN; INJECTION SITE; LIVER TOXICITY; MALABSORPTION; NAUSEA; NONHUMAN; PILOT STUDY; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; URTICARIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNE SYSTEM DISEASES; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 0038518183     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Cash JM, Klippel JH: Second-line drug therapy for rheumatoid arthritis. N Engl J Med (1994) 330(19):1368-1375.
2. Reichlin S: Neuroendocrine interactions. N Engl J Med (1993) 329(17):1246-1253.
3. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (1973) 179(68):77-79.
4. Lamberts SW, Van Der Lely AJ, De Herder WW, Hofland LJ: Octreotide. N Engl J Med (1996) 334(4):246-254. A comprehensive review of octreotide.
5. Nio DA, Moyland RN, Roche JK: Modulation of T lymphocyte function by neuropeptides. Evidence for their role as immunoregulatory elements. J Immunol (1993) 150(12):5281-5288.
6. Fais S, Annibale B, Boirivant M, Santoro A, Pallone F, Delle Fave G: Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation. J Neuroimmunol (1991) 31(3):211-219.
7. Kolansinski SL, Haines KA, Siegel EL, Cronstein BN, Abramson SB: Neuropeptides and inflammation: A somatostatin analog as a selective antagonist of neutrophil activation by substance P. Arthritis Rheum (1992) 35(4):369-375.
8. Evers BM, Parekh D, Townsend CM Jr, Thompson JC: Somatostatin and analogs in the treatment of cancer. A review. Ann Surg (1991) 213(3):190-198.
9. Barrie R, Woltering EA, Hajarizadeh G, Mueller C, Ure T, Fletcher WS: Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res (1993) 55(4):446-450.
10. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol (1999) 20(3):157-198.
11. Benali N, Ferjoux G, Puente E, Buscail L, Susini C: Somatostatin receptors. Digestion (2000) 62(Suppl 1):27-32.
12. Schonbrunn A: Somatostatin receptors present knowledge and future directions. Ann Oncol (1999) 10(Suppl 2):S17-S21.
13. Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV: SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-γ release. Eur J Immunol (1999) 29(8):2454-2463.
14. Ten Bokum AMC, Melief MJ, Schonbrunn A, Van Der Ham F, Lindeman J, Hofland LJ, Lamberts SWJ, Van Hagen PM: Immunohistochemical localization of somatostatin receptor sst2A in human rheumatoid synovium. J Rheumatol (1999) 26(7):532-535.
15. Van Hagen PM, Markusse HM, Lamberts SWJ, Kwekkeboom DJ, Reubi JC, Krenning EP: Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum (1994) 37(10):1521-1527.
16. Patel YC, Srikant CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology (1994) 135(6):2814-2817.
17. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jimenez F et al: Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (2000) 53(5):577-586.
18. Payan DG, Goetzl EJ: Modulation of lymphocyte function by sensory neuropeptides. J Immunol (1985) 132(2 Suppl):783S-786S.
19. Van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Lowenberg B, Lamberts SW: Somatostatin and the immune and hematopoietic system; A review. Eur J Clin Invest (1994) 24(2):91-99.
20. Chowers Y, Cahalon L, Lahav M, Schor H, Tal R, Bar-Meir S, Levite M: Somatostatin through its specific receptor inhibits spontaneous and TNFα- and bacteria-induced IL-8 and IL-1β secretion from intestinal epithelial cells. J Immunol (2000) 165(6):2955-2961.
21. Karalis K, Mastorakos G, Chrousos GP, Tolis G: Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest (1994) 93(5):2000-2006.
22. Muscettola M, Grasso G: Somatostatin and vasoreactive intestinal peptide reduce interferon-γ production by human peripheral blood mononuclear cells. Immunobiology (1990) 180(4-5):419-430.
23. Takeba Y, Suzuki N, Takeno M, Asai T, Tsuboi S, Hoshino T, Sakane T: Modulation of synovial cell function by somatostatin in patients with rheumatoid arthritis. Arthritis Rheum (1997) 40(12):2128-2138. A pivotal study demonstrating the role of somatostatin as a modulator of synovial cell function in RA.
24. Matucci-Cerinic M, Borrelli F, Generini S, Cantelmo A, Marcucci I, Martelli F, Romagnoli P, Bacci S, Conz A, Marinelli P et al: Somatostatin-induced modulation of inflammation in experimental arthritis. Arthritis Rheum (1995) 38(11):1687-1693.
25. Berczi I, Nagy E, Asa SL, Kovacs K: The influence of pituitary hormones on adjuvant arthritis. Arthritis Rheum (1984) 27(6):682-688.
26. Berczi I, Baragar FD, Chalmers IM, Keystone EC, Nagy E, Warrington RJ: Hormones in self-tolerance and autoimmunity: A role in the pathogenesis of rheumatoid arthritis? Autoimmunity (1993) 16(1):45-56.
27. Elhassan AM, Adem A, Papadogiannakis N, Suliman I, Gad A, Lindgren JU: Intracerebroventricular administration of somatostatin prevents and attenuates adjuvant arthritis. J Neuroimmunol (2001) 116(1):15-20.
28. Sakane T, Suzuki N: The role of somatostatin in the pathophysiology of rheumatoid arthritis. Clin Exp Rheumatol (1998) 16(6):745-749. A review of the studies concerning the role of somatostatin in the pathophysiology of RA.
29. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J: Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res (1991) 50(3):245-251.
30. Paran H, Paran D: Angiogenesis and tumor growth. N Engl J Med (1996) 334(14):921.
31. Koch AE: Review: Angiogenesis: Implications for rheumatoid arthritis. Arthritis Rheum (1998) 41(6):951-962. A review of the role of angiogenesis in the pathophysiology of RA.
32. Kuraishi Y, Hirota N, Sato Y, Hino Y, Satoh M, Takagi H: Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res (1985) 324(1-2):294-298.
33. Chrubasik J, Meynadier J, Blond S, Scherpereel P, Ackerman E, Weinstock M, Bonath K, Cramer H, Wunsch E: Somatostatin, a potent analgesic. Lancet (1984) 2(8413):1208-1209.
34. Matucci-Cerinic M, Lotti T, Cappugi P, Boddi V, Fattorini L,Panconesi E: Somatostatin treatment of psoriatic arthritis. Int J Dermatol (1998) 27(1):56-68.
35. Matucci-Cerinic M, Marabini S: Somatostatin treatment for pain in rheumatoid arthritis; A double blind versus placebo study in knee involvement. Med Sci Res (1988) 16:233-234.
36. Fioravanti A, Govoni M, La Montagna G, Perpignano G, Tirri G, Trotta F, Bogliolo A, Ciocci A, Mauceri MT, Marcolongo R: Somatostatin 14 and joint inflammation: Evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis. Drugs Exp Clin Res (1995) 21(3):97-103.
37. Coari G, Di Franco M, Iagnocco A, Di Novi MR, Mauceri MT, Ciocci A: Intra-articular somatostatin 14 reduces synovial thickness in rheumatoid arthritis: An ultrasonographic study. Int J Clin Pharmacol Res (1995) 15(1):27-32.
38. Matucci-Cerinic M, Pignone A, Lotti T, Partsch G, Livi R, Cagnoni M: Gold salts and somatostatin: A new combined analgesic treatment for psoriatic arthritis. Drugs Exp Clin Res (1992) 18(2):53-61.
39. Paran D, Elkayam O, Mayo A, Paran H, Amit M, Yaron M, Caspi D: A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis. Ann Rheum Dis (2001) 60(9):888-891. The first study of long-acting somatostatin analog treatment for RA. A beneficial effect is demonstrated.
40. Koseoglu F, Koseoglu T: Long acting somatostatin analogue for the treatment of refractory RA. Ann Rheum Dis (2002) 61(6):573-574.
41. Grasland A, Pouchot J, Vinceneux P, Ruszniewski P: Onset of rheumatoid arthritis following curative treatment of a somatostatinoma. Arthritis Rheum (2002) 46(1):277-278.